Swiss biotech ImmunOs Therapeutics today announced the appointment of Dr Constanze Guenther as senior vice president, CMC and technical development. 19 September 2023
Leading Indian drugmaker Sun Pharmaceutical Industries has entered into a license agreement with US privately-held biopharma Pharmazz to commercialize a first-in-class innovative drug, Tyvalzi (sovateltide) in India. 18 September 2023
A novel antibody developed by Anthos Therapeutics, a cardiovascular specialist founded by Blackstone Life Sciences, has performed well in a Phase II trial. 18 September 2023
Citing resource constraints for the decision, the US Food and Drug Administration (FDA) says requires additional time to complete the Priority Review of Iovance Biotherapies’ Biologics License Application (BLA) for lifileucel. 18 September 2023
UK-based lifecycle management and pharma manufacturing company Pharmanovia today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from French pharma major Sanofi. 18 September 2023
Germany-based mRNA specialist CureVac, in collaboration with UK pharma major GSK, recently announced the advancement of its multivalent valent, modified seasonal influenza mRNA vaccine candidate into Phase II clinical trials. 15 September 2023
A new US biotech, Arialys Therapeutics, which is pioneering new therapeutics for autoimmune neuropsychiatry, has announced the closing of $58 million in seed financing. 15 September 2023
US health technology assessor the Institute for Clinical and Economic Review ICER) today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of atidarsagene autotemcel (“arsa-cel”), from USA and UK-based Orchard Therapeutics, for metachromatic leukodystrophy (MLD). 14 September 2023
AlveoGene, a UK-based company focused on transforming rare respiratory disease outcomes using inhaled gene therapy has announced its launch. 14 September 2023
US biopharma firm Eiger BioPharmaceuticals saw its shares plummet more than 40% to $0.41, after it announced its decision to discontinue the Phase III LIMT-2c study of peginterferon lambda in patients with chronic hepatitis delta (CHD). 14 September 2023
Stock in New Jersey, USA-based Rocket Pharmaceuticals shot up around 40% on Wednesday, following good news on the financing and regulatory fronts. 14 September 2023
In France, a recently-founded biotech focused on the tumor microenvironment has agreed terms for a licensing and co-development program with SATT Nord. 14 September 2023
Shares of London-listed blood disease specialist Hemogenyx Pharmaceuticals were up more than 9% at 1.80 pence, after it revealed in a stock exchange filing a positive development for its investigational product. 14 September 2023
US genomics-based drug discovery company Exelixis has entered into an exclusive license agreement with Sino-American firm Insilico Medicine for global rights to develop and commercialize the latter’s ISM3091. 13 September 2023
US biotech start-up Septerna says it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals under which Vertex has acquired an undisclosed discovery-stage GPCR program. 13 September 2023
US cell and gene therapy biotech 2seventy bio had a bumpy ride this morning, after it announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. 12 September 2023
Chinese biopharma Hutchmed today announced positive results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (MET) exon 14 skipping alteration non-small cell lung cancer (NSCLC). 12 September 2023
Privately-held Swedish firm Salipro Biotech has entered into a research collaboration with Japan's Sumitomo Pharma to reveal the mechanism of action and pharmacological characterization of a drug candidate. 12 September 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024